Delving into the Latest Updates on Bioinova, s.r.o. with Synapse

概览

关联

2

项与 Bioinova, s.r.o. 相关的药物

Autologous Mesenchymal Cells(Bioinova, s.r.o.)

靶点-

作用机制-

在研机构-

原研机构

Bioinova, s.r.o.

在研适应症-

非在研适应症

肌萎缩侧索硬化 [+2]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

Mesenchymal stem cell therapy (Bioinova)

靶点-

作用机制

细胞替代物

在研机构-

原研机构

Bioinova, s.r.o.

在研适应症-

非在研适应症

软骨疾病 [+2]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

7

项与 Bioinova, s.r.o. 相关的临床试验

EUCTR2018-004067-31-CZ / Not yet recruiting临床1/2期IIT

Autologous bone marrow-derived mesenchymal stem cells seeded on a 3D scaffold in treatment of knee cartilage defects. Prospective open-label study to assess safety and feasibility.

开始日期2018-12-21

申办/合作机构

Bioinova, s.r.o.

NCT03827096 / Terminated临床1/2期

Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease to Assess the Safety and the Efficacy

Subjects in whom a posterolateral fusion surgery has been planned and who meet the inclusion and exclusion criteria were proposed to receive a single-dose AMSC treatment, in order to assess its safety and efficacy on posterolateral interbody fusion. After the surgery, the subjects were followed up as out-patients during 5 study visits for 12 months in total.

开始日期2013-08-27

申办/合作机构

Bioinova, s.r.o.

EUCTR2010-024665-52-CZ / Not yet recruiting临床2期IIT

Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease: a Prospective, Non-randomized, Open-Label Study to Assess the Safety and the Efficacy. - Autologous MCS effect in union of vertebrae after spinal surgery.

开始日期2013-07-24

申办/合作机构

Bioinova, s.r.o.

100 项与 Bioinova, s.r.o. 相关的临床结果

登录后查看更多信息

0 项与 Bioinova, s.r.o. 相关的专利（医药）

登录后查看更多信息

100 项与 Bioinova, s.r.o. 相关的药物交易

登录后查看更多信息

100 项与 Bioinova, s.r.o. 相关的转化医学

登录后查看更多信息